SDMA

• UNSPSC Description:

  SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

• Target Antigen:

  Endogenous Metabolite; NF-κB; NO Synthase

• Type:

  Natural Products

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/SDMA.html

• Purity:

  98.0

• Solubility:

  DMSO : 67.5 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  N[C@@H](CCC/N=C(NC)/NC)C(O)=O

• Molecular Weight:

  202.25

• References & Citations:

  [1]Bode-Böger SM,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent ofcoronary artery disease.|[2]Schepers E, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.Clin J Am Soc Nephrol. 2011 Oct;6(10):2374-83.|[3]Nabity MB, et al. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the EarlyDetection of Chronic Kidney Disease in Dogs. J Vet Intern Med. 2015 Jul-Aug;29(4):1036-44.|[4]Veldink H, et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. Nephrol Dial Transplant. 2013 Jun;28(6):1434-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  30344-00-4